Clinical Trial Update: APRiCOT-L: Study to Evaluate Efficacy and Safety of Apricoxib With Erlotinib in Patients With Non-small Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating the combination of apricoxib and erlotinib in patients with recurrent non-small cell lung cancer has completed and posted results in …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Apricoxib (apricoxib)
• ERLOTINIB (Erlotinib)

Snippet

Sponsor: Tragara Pharmaceuticals, Inc. | Conditions: Recurrent Non Small Cell Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2012-04-09